Categories: Health

Interim report H1 2025

9% organic sales growth in H1 and FY outlook range narrowed to 6-8%

Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth.  Our profitability also remains solid, despite strong headwinds from currencies. With a robust foundation in place, we are well positioned to accelerate into our next strategy period until 2030, where we will continue to significantly invest in what makes Novonesis unique, further strengthening our position while expanding the biosolutions market.”

  • Strong organic sales growth of 9% (Q2: 8%), including ~1pp from price (Q2: ~1pp). Food & Health at 10% organic sales growth (Q2: 9%); Planetary Health at 9% organic sales growth (Q2: 7%).
  • Emerging markets organic sales growth at 12% (Q2: 10%) and developed markets at 8% (Q2: 6%).
  • Cost synergies now at 100% run rate compared to 80% previously.
  • Adjusted EBITDA margin at 37.4% (Q2: 36.4%), up by 210 bps (Q2: up by 100 bps).
  • Adjusted net profit increased by 23% (Q2: 19%).
  • NIBD/EBITDA at 2.1x, including the closed acquisition of dsm-firmenich’s part of the Feed Enzyme Alliance on June 2, 2025.
  • Completion of the EUR 100 million share buyback program on June 27.
  • 2025 outlook: Organic sales growth range narrowed to 6-8% (previously 5-8%), and 7-9% excluding the exit from certain countries (previously 6-9%). Adjusted EBITDA margin is maintained at 37-38%, despite strong currency headwinds.
  • Interim dividend of 2.25 DKK (EUR 0.30) approved for the first half of 2025.
  • Long-term financial targets for 2030 announced. Please refer to the Company Announcement from August 20, 2025.

Please read the full announcement in PDF

GlobeNews Wire

Recent Posts

Altair and Wichita State University’s NIAR Sign MoU to Accelerate Aerospace Innovation

Collaboration will expand digital twin adoption, empower aerospace startups, and speed up product development and…

2 hours ago

Public Interest Registry Welcomes Applications for its Advisory Council

RESTON, Va., Sept. 10, 2025 /PRNewswire/ -- Public Interest Registry (PIR) announced today that it…

2 hours ago

NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program

The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to start the IND-enabling…

2 hours ago

KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025

RIYADH, Saudi Arabia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research…

2 hours ago

MG 3 receives four stars but suffers rare and serious seat failure in Euro NCAP crash test

LEUVEN, BELGIUM – For decades, MG’s catchy slogan was ‘Safety Fast’ as the British marque…

2 hours ago

Ten athlete ambassadors engaged in preventing competition manipulation announced

10 September 2025 – Ten athletes from every continent and 10 different sports have been…

3 hours ago